Teva's version of generic Lovenox, which is manufactured and tested outside of the U.S." That defense disappears as soon as Teva attempts to market in the U.S. (which is the entire basis for the ANDA to begin with).
What if their research and tweaking of the process to manufacture the molecule made use of techniques that overlap MNTA's patent, but the end manufacturing process (including quality control) uses techniques that do not infringe? That would be my guess for one of their defenses.